Opinion on Drug Delivery

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth: wider benefits for Prevnar

Research from Kaiser Permanente suggests that widespread immunization with Prevnar reduces the incidence of pneumococcal infections in adults and older children. This and other similar studies should help to establish greater demand for Prevnar, which has yet to entirely fulfill its potential due to its relatively high cost.

Published By Datamonitor
05 May 2004
CommentWire
CommentWire

Wyeth/MedImmune: the end of the road for FluMist venture

Following poor first-year performance, Wyeth [WYE] and MedImmune [MEDI] have announced the dissolution of their FluMist partnership. If MedImmune is to achieve success with this product alone, it may need to rethink its premium pricing strategy.

Published By Datamonitor
28 Apr 2004
CommentWire
CommentWire

Wyeth/MedImmune: second generation vaccine

Wyeth [WYE] and MedImmune's [MEDI] FluMist failed to secure indications for use in key target groups for influenza vaccine in the US. Recently released results suggest that their second generation product may enable the two companies to capitalize on more conventional influenza vaccine sectors.

Published By Datamonitor
15 Oct 2003
Expert View
Expert View

World Vaccine Congress Asia: vast regional diversity requires flexibility and targeted portfolios

Spanning one third of the globe's circumference and home to more than half of the world's population, the Asia Pacific region is incredibly diverse. This year's World Vaccine Congress Asia highlighted the enormous variation in the vaccine landscape in the region, owing to a myriad of political, cultural, economic and geographic differences.

Published By Datamonitor
24 Jun 2009
Expert View
Expert View

World Vaccine Congress Asia: new partnerships open doors to regional markets

At the World Vaccine Congress Asia, it became apparent that new local facilities and partnerships are essential to expand supply, thus providing openings into the emerging vaccine markets of the region. GlaxoSmithKline and Sanofi Pasteur are leading in the space, overcoming low levels of disease awareness and financial shortages to secure a strong foothold in Asia.

Published By Datamonitor
24 Jun 2009
ResearchWire
ResearchWire

Women's health: patches will steal market share from oral contraceptives

Published By Datamonitor
21 Feb 2002
Expert View
Expert View

Will contraceptive patches challenge the pill?

Although the contraceptive pill has been hugely successful, remembering to take it every day can be a problem. Alternative delivery methods such as implants and injections, meanwhile, have proved unpopular. The contraceptive patch could fill the middle ground, potentially cutting unwanted pregnancies - but will it? Datamonitor women's health analyst Jane Richardson cuts through the hype...

Published By Datamonitor
28 Mar 2002
Expert View
Expert View

Waste not, want not: drug delivery to the rescue

Published By Datamonitor
22 Sep 2000
CommentWire
CommentWire

Vaccines: less pain, more gain

Patients' fear of immunization may be reduced, as new technology provides alternatives to the dreaded needle. Vaccines could soon be administered through nasal inhalation, orally or even across the skin using patches. The efficacy of these methods, coupled with increased receptiveness, will greatly reduce needle use in vaccination over the next ten years.

Published By Datamonitor
30 Jan 2002
CommentWire
CommentWire

Vaccines: Intercell buys Iomai

Intercell has acquired Iomai for $189 million, in a deal motivated by the Austrian company's desire to gain ownership of Iomai's traveler's diarrhea vaccine and transdermal delivery technology. With the potential to deliver both vaccine and adjuvant, independently, through Iomai's transdermal patch, Intercell's development of its proprietary adjuvant IC31 may also benefit from the technology.

Published By Datamonitor
13 May 2008

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.